These are two extracts from Biotron's last Half Yearly Report...

These are two extracts from Biotron's last Half Yearly Report ending December 31st 2017:

1- The purpose of this clinical trial is to demonstrate that the addition of BIT225 to current anti-HIV-1 drug treatments resultsin an additional, measurable benefit to patients. This is the key outcome that needs to be demonstrated to potentialcommercial partners.

2- The Company remains focused on achieving a commercial outcome for its antiviral programs in worldwide markets,including the USA, Europe and China. The major focus is on partnering the HIV-1 program. Meetings have been held withpotential partners throughout the period under review, and further meetings are anticipated during the second half of thefinancial year once the Company has data from the current HIV-1 clinical trial in hand.

Meetings with potential partners have been ongoing for some time now according to the commentary coming from the company, with the anticipation of the latest successful trial results which we saw in September. 
As Michelle Miller stated back in 2014 on Sky business when asked the question - the estimated time frame to potentially have a product on the market is around 3-5 years.